Jump to main content
Jump to site search
SCHEDULED MAINTENANCE Close the message box

Maintenance work is planned for Monday 16 August 2021 from 07:00 to 23:59 (BST).

Website performance may be temporarily affected and you may not be able to access some PDFs or images. If this does happen, refreshing your web browser should resolve the issue. We apologise for any inconvenience this might cause and thank you for your patience.

All chapters

Peptide-derived mid-sized anti-HIV agents

To date, several anti-human immunodeficiency virus (HIV) drugs such as reverse transcriptase inhibitors, protease inhibitors and integrase inhibitors have been developed, and the use in combination of these drugs has brought great success in the treatment of HIV-infected and acquired immunodeficiency syndrome (AIDS) patients. We have produced several anti-HIV agents including fusion inhibitors, coreceptor antagonists, integrase inhibitors, CD4 mimics and matrix peptides, and vaccines. These have been developed from the corresponding peptides and proteins. The number of available potent drugs is limited and entry inhibitors such as CCR5/CXCR4 antagonists and CD4 mimics, fusion inhibitors, vaccines and allosteric type integrase inhibitors might be useful for an expansion of the drug repertoire. This chapter is an update of our contribution on the topic of peptide-derived anti-HIV agents with a focus on mid-size drugs.

Publication details

Print publication date
25 Nov 2016
Copyright year
Print ISBN
ePub eISBN